Company news

Lixte Biotechnology Holdings, Inc. news in 2023

Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2023, newest first.

View company

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

November 12, 2023

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

October 8, 2023

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

September 25, 2023

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

September 19, 2023

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

July 17, 2023

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

June 22, 2023

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

June 6, 2023

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

June 1, 2023

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

April 23, 2023

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

April 3, 2023

LIXTE Biotechnology Holdings, Inc. reports that its lead clinical compound, LB-100, can kill cancer cells through hyper-stimulation of cell proliferation signals in pre-clinical models

February 6, 2023